Prediction models for the viability of pulmonary metastatic lesions after chemotherapy in nonseminomatous germ cell tumors. 2020

Hiroaki Tsunezuka, and Terukazu Nakamura, and Kei Fujikawa, and Masanori Shimomura, and Satoru Okada, and Junichi Shimada, and Satoshi Teramukai, and Osamu Ukimura, and Masayoshi Inoue
Division of Thoracic Surgery, Department of Surgery, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.

OBJECTIVE To analyze predictors associated with viable cells in pulmonary residual lesions after chemotherapy for metastatic testicular nonseminomatous germ cell tumors and to develop models to prioritize pulmonary resection. METHODS Between 2008 and 2017, 40 patients underwent pulmonary metastasectomy after chemotherapy for nonseminomatous germ cell tumors. We evaluated these patients, and 326 pulmonary residual lesions were confirmed using computed tomography and pathological evaluations. Relationships with outcomes were analyzed using logistic regression analyses. Risk prediction models were developed, and predictive probabilities for the risk of viable cells were estimated. RESULTS Histological examinations showed that 73 (22%) pulmonary residual lesions contained viable cells: teratomas, 46 (14%); and cancer cells, 37 (11%). Multivariate analyses showed that the predictors associated with cancer cells in the residual lesions were elevated tumor marker levels, multiregimen chemotherapy, increased tumor size 6 months before surgery and the histological composition of the primary lesion, including yolk sac tumors. Additional predictors associated with teratomas were aspect ratio and histological composition of the primary lesion, including teratomas. CONCLUSIONS Intratumoral heterogeneity contributes to nonseminomatous germ cell tumor chemoresistance, and primary lesion site yolk sac tumors and teratomas are associated with greater risks of viable cells. Increased residual lesion size during chemotherapy could also be a predictor. Our simple model can predict the presence of viable cells in residual lesions after chemotherapy, and it might assist in decision-making and prioritizing pulmonary residual lesion resection.

UI MeSH Term Description Entries
D008297 Male Males
D009373 Neoplasms, Germ Cell and Embryonal Neoplasms composed of primordial GERM CELLS of embryonic GONADS or of elements of the germ layers of the EMBRYO, MAMMALIAN. The concept does not refer to neoplasms located in the gonads or present in an embryo or FETUS. Germ Cell Cancer,Germ Cell Tumor,Neoplasms, Embryonal and Mixed,Cancer, Embryonal,Cancer, Embryonal and Mixed,Embryonal Neoplasms,Germ Cell Neoplasms,Germ Cell and Embryonal Neoplasms,Germ Cell and Embryonic Neoplasms,Neoplasms, Embryonal,Neoplasms, Germ Cell,Neoplasms, Germ Cell and Embryonic,Cancer, Germ Cell,Cancers, Embryonal,Cancers, Germ Cell,Embryonal Cancer,Embryonal Cancers,Embryonal Neoplasm,Germ Cell Cancers,Germ Cell Tumors,Neoplasm, Embryonal,Tumor, Germ Cell,Tumors, Germ Cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013724 Teratoma A true neoplasm composed of a number of different types of tissue, none of which is native to the area in which it occurs. It is composed of tissues that are derived from three germinal layers, the endoderm, mesoderm, and ectoderm. They are classified histologically as mature (benign) or immature (malignant). (From DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1642) Dysembryoma,Teratoid Tumor,Teratoma, Cystic,Teratoma, Mature,Teratoma, Benign,Teratoma, Immature,Teratoma, Malignant,Benign Teratoma,Benign Teratomas,Dysembryomas,Immature Teratoma,Immature Teratomas,Malignant Teratoma,Malignant Teratomas,Teratoid Tumors,Teratomas,Teratomas, Benign,Teratomas, Immature,Teratomas, Malignant,Tumor, Teratoid,Tumors, Teratoid
D013736 Testicular Neoplasms Tumors or cancer of the TESTIS. Germ cell tumors (GERMINOMA) of the testis constitute 95% of all testicular neoplasms. Cancer of Testis,Cancer of the Testes,Testicular Cancer,Testicular Neoplasm,Testicular Tumor,Testis Cancer,Cancer of the Testis,Neoplasms, Testicular,Neoplasms, Testis,Testicular Tumors,Testis Neoplasms,Tumor of Rete Testis,Cancer, Testicular,Cancer, Testis,Cancers, Testicular,Cancers, Testis,Neoplasm, Testicular,Neoplasm, Testis,Rete Testis Tumor,Rete Testis Tumors,Testicular Cancers,Testis Cancers,Testis Neoplasm,Testis Tumor, Rete,Testis Tumors, Rete,Tumor, Testicular,Tumors, Testicular

Related Publications

Hiroaki Tsunezuka, and Terukazu Nakamura, and Kei Fujikawa, and Masanori Shimomura, and Satoru Okada, and Junichi Shimada, and Satoshi Teramukai, and Osamu Ukimura, and Masayoshi Inoue
May 2020, International journal of urology : official journal of the Japanese Urological Association,
Hiroaki Tsunezuka, and Terukazu Nakamura, and Kei Fujikawa, and Masanori Shimomura, and Satoru Okada, and Junichi Shimada, and Satoshi Teramukai, and Osamu Ukimura, and Masayoshi Inoue
March 1996, The Journal of urology,
Hiroaki Tsunezuka, and Terukazu Nakamura, and Kei Fujikawa, and Masanori Shimomura, and Satoru Okada, and Junichi Shimada, and Satoshi Teramukai, and Osamu Ukimura, and Masayoshi Inoue
January 1990, Progress in clinical and biological research,
Hiroaki Tsunezuka, and Terukazu Nakamura, and Kei Fujikawa, and Masanori Shimomura, and Satoru Okada, and Junichi Shimada, and Satoshi Teramukai, and Osamu Ukimura, and Masayoshi Inoue
January 1997, Cancer,
Hiroaki Tsunezuka, and Terukazu Nakamura, and Kei Fujikawa, and Masanori Shimomura, and Satoru Okada, and Junichi Shimada, and Satoshi Teramukai, and Osamu Ukimura, and Masayoshi Inoue
January 1998, Oncology,
Hiroaki Tsunezuka, and Terukazu Nakamura, and Kei Fujikawa, and Masanori Shimomura, and Satoru Okada, and Junichi Shimada, and Satoshi Teramukai, and Osamu Ukimura, and Masayoshi Inoue
August 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
Hiroaki Tsunezuka, and Terukazu Nakamura, and Kei Fujikawa, and Masanori Shimomura, and Satoru Okada, and Junichi Shimada, and Satoshi Teramukai, and Osamu Ukimura, and Masayoshi Inoue
November 1984, Seminars in urology,
Hiroaki Tsunezuka, and Terukazu Nakamura, and Kei Fujikawa, and Masanori Shimomura, and Satoru Okada, and Junichi Shimada, and Satoshi Teramukai, and Osamu Ukimura, and Masayoshi Inoue
October 1996, The Journal of urology,
Hiroaki Tsunezuka, and Terukazu Nakamura, and Kei Fujikawa, and Masanori Shimomura, and Satoru Okada, and Junichi Shimada, and Satoshi Teramukai, and Osamu Ukimura, and Masayoshi Inoue
May 2007, The Urologic clinics of North America,
Hiroaki Tsunezuka, and Terukazu Nakamura, and Kei Fujikawa, and Masanori Shimomura, and Satoru Okada, and Junichi Shimada, and Satoshi Teramukai, and Osamu Ukimura, and Masayoshi Inoue
November 2002, Seminars in urologic oncology,
Copied contents to your clipboard!